Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 23, 2017 02:00 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Present Updated Hemophilia B Data at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress

PHILADELPHIA, June 23, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
June 01, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Participate in Multiple Conferences in June

PHILADELPHIA, June 01, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
May 18, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Completes Rolling Biologics License Application Submission to FDA for Investigational Gene Therapy Voretigene Neparvovec

PHILADELPHIA, May 18, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
May 09, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Progress

Work on U.S. Biologics License Application (BLA) for investigational voretigene neparvovec is complete Interim results from SPK-7001 Phase 1/2 clinical trial in choroideremia reported;...
May 03, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Participate in Multiple Meetings in May

PHILADELPHIA, May 03, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
May 02, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Host Conference Call on Tuesday, May 9 at 8:30 a.m. to Discuss Q1 2017 Results

PHILADELPHIA, May 02, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
April 06, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Presents Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at the Hemostasis and Thrombosis Research Society (HTRS) 2017 Scientific Symposium

As of data cutoff, the annualized bleeding rate (ABR) has been reduced by 96 percent and the annualized infusion rate (AIR) reduced by 99 percent Both participants who began a tapering course of...
April 04, 2017 16:15 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Present Updated Hemophilia B Data at the Hemostasis and Thrombosis Research Society (HTRS) 2017 Scientific Symposium

PHILADELPHIA, April 04, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
March 02, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Participate in Multiple Conferences in March

PHILADELPHIA, March 02, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
March 01, 2017 16:15 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency

PHILADELPHIA and NEW YORK, March 01, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) announced today that SPK-9001, the lead investigational candidate in the...